Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST) – early results of RTOG 0132

BACKGROUND: Therapy for gastrointestinal stromal tumors (GIST) has changed significantly with the use of Imatinib Mesylate (IM). Despite the success of this drug in metastatic GIST, disease progression remains a perplexing clinical issue suggesting the need for multimodality management. There have b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Eisenberg, Burton L., Harris, Jonathan, Blanke, Charles, Demetri, George D., Heinrich, Michael C., Watson, James C., Hoffman, John P., Okuno, Scott, Kane, John M., von Mehren, Margaret
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2606912/
https://ncbi.nlm.nih.gov/pubmed/18942073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jso.21160
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados